|1.||Meltzer, Herbert Y: 65 articles (01/2016 - 03/2002)|
|2.||Lieberman, Jeffrey A: 39 articles (01/2016 - 02/2002)|
|3.||Remington, Gary: 33 articles (10/2015 - 01/2002)|
|4.||Correll, Christoph U: 26 articles (10/2015 - 01/2007)|
|5.||Kennedy, James L: 25 articles (01/2016 - 10/2002)|
|6.||Kane, John M: 25 articles (10/2015 - 01/2002)|
|7.||Green, Alan I: 21 articles (10/2015 - 04/2002)|
|8.||Kelly, Deanna L: 20 articles (11/2015 - 03/2003)|
|9.||Freudenreich, Oliver: 20 articles (01/2013 - 02/2004)|
|10.||Henderson, David C: 19 articles (05/2015 - 01/2002)|
|1.||Schizophrenia (Dementia Praecox)
12/01/2007 - "The study of anatomic and functional brain variables associated with clozapine response in schizophrenia may help to identify patients who are most likely to benefit from clozapine treatment. "
11/01/1990 - "Clinical studies have shown clozapine to be effective in suppressing both the positive and negative symptoms of schizophrenia and to be associated with an extremely low incidence of extrapyramidal side effects. "
11/01/2015 - "Clozapine (CLZ) is the most effective treatment for treatment-resistant schizophrenia (SCZ) patients, with potential added benefits of reduction in suicide risk and aggression. "
07/01/2015 - "Clozapine is the most effective treatment for treatment-resistant schizophrenia but its use is suboptimal. "
09/20/2014 - "Clozapine is a unique anti-psychotic medication that is most effective in the treatment of refractory schizophrenia and reducing suicidality. "
03/01/1995 - "Presented here is a case of clozapine overdose treated successfully with supportive care in which agranulocytosis did not develop."
09/01/1999 - "The atypical antipsychotic agent clozapine is known to be effective in schizophrenic patients refractory to other medications; however, it induces agranulocytosis in approximately 1-2%. "
05/01/2011 - "Evidence of efficacy for psychosis and safety for motor side effects is strongest for clozapine but routine use of clozapine is limited by its potential to cause agranulocytosis and the stringent monitoring requirements. "
09/14/2006 - "Thus functional data derived from the in vitro stromal system defined in these studies may enable further investigation of the mechanisms subserving stromal impairment in clozapine-induced agranulocytosis and direct attention to improved methods for its prevention."
12/01/1996 - "Clozapine does not constitute a first-line treatment due to the occurrence of agranulocytosis. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
01/01/2010 - "Clozapine is the most effective treatment for patients with refractory psychotic disorders and is also effective for reducing suicidal and violent behavior in this same population. "
08/01/1997 - "The atypical antipsychotic clozapine has been reported to be effective in otherwise refractory psychoses. "
04/01/1995 - "Clozapine was an effective treatment for refractory psychotic disorders when given as a part of routine state hospital treatment."
01/01/2002 - "Clozapine has shown consistent efficacy against positive symptoms of psychoses, and emerging reports indicate improvements in aggression and suicidality. "
05/01/1994 - "Advances in the nosology of schizoaffective disorder, emerging epidemiologic data demonstrating large numbers of patients with this disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of schizoaffective disorder, suggest that renewed interest in the diagnosis and treatment of this disorder may lead to improved delivery of care for this understudied but seriously ill group of patients."
|4.||Bipolar Disorder (Mania)
06/01/2015 - "In the current study, we sought to disentangle the effect of clozapine from that of improved treatment regularity and to compare the effect of clozapine with the effect of regular treatment for bipolar disorder by exploring the complete 10-year clozapine prescription data from a Taiwanese total population health claims database. "
06/01/2015 - "Clozapine, when used with high treatment regularity (MPR > 0.8), was effective in reducing the numbers of ER visits, hospitalizations, and total hospital days in patients with bipolar disorder with previous frequent hospitalizations and ER visits despite regular pre-clozapine treatment for bipolar disorder. "
08/01/2004 - "Clozapine is more effective in NRC patients with a history of mania in comparison to patients with a recent history of RC."
06/01/2000 - "The findings from this open-label study, which are consistent with previous retrospective studies, case reports, and one other open-label prospective study, suggest that clozapine is an effective agent for patients with treatment-refractory psychotic mania."
12/01/2014 - "This is also true for clozapine, which can be effective in therapy-refractory courses of bipolar disorder. "
|5.||Movement Disorders (Movement Disorder)
10/01/1984 - "With this in mind, the authors present the case of a 32-year-old chronically institutionalized schizophrenic who showed a remarkable improvement in both tardive dyskinesia and psychotic symptoms following an open trial of clozapine, 900 mg daily. "
01/01/1994 - "Clozapine, the best studied of these agents, is also superior in efficacy with regard to psychopathology and cognitive function and has been shown not to cause tardive dyskinesia. "
09/01/1993 - "With the advent of clozapine, patients with preexisting tardive dyskinesia began therapy and their symptoms did not worsen--and, in many cases, their symptoms improved dramatically. "
03/01/1996 - "Sixteen months of clozapine treatment led to significant reduction of symptomatology with marked improvement in social functioning and diminished tardive dyskinesia. "
05/01/1995 - "It has been suggested that clozapine may be beneficial for the treatment of tardive dyskinesia in adolescents. "
|1.||Antipsychotic Agents (Antipsychotics)
|3.||Risperidone (Risperdal Consta)
|8.||Levodopa (L Dopa)
|1.||Drug Therapy (Chemotherapy)